Gilead Sciences (GILD) to Release Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $7.15 billion for the quarter. Gilead Sciences has set its FY24 guidance at $4.25-4.45 EPS and its FY 2024 guidance at 4.250-4.450 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm earned $2.29 earnings per share. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $98.38 on Tuesday. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $99.45. The firm has a 50-day moving average price of $92.42 and a two-hundred day moving average price of $85.96. The company has a market capitalization of $122.61 billion, a P/E ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 598,414 shares of company stock valued at $55,953,200. 0.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on GILD shares. Wolfe Research started coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective on the stock. Bank of America reaffirmed a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Finally, Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.